AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback